drugset / Trial / NCT02962245

Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis

NCT02962245

RandomizedParallel-groupOpen-labelTreatment

Summary

The research aim to find out whether berberine can reduce the annual recurrence rate of ulcerative colitis in remission. A total of 238 patients with ulcerative colitis in remission will be randomly divided into two groups.One will receive regular treatment,and the other group will receive extra oral berberine 300 mg three times daily for a year. The end of the study for every patient is disease recurrence(Mayo Clinic score of 3 points or more ). The primary analysis is annual recurrence rate, and both endoscopy and Mayo Clinic disease activity index scores at the baseline and final assessments.

Timeline

Start
2016-11
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Berberine Traditional medicine (herbal / TCM) 300 mg Oral

Indications